FLAURA2: Should this Positive Trial Change Practice for EGFRm+ NSCLC [Video]

Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive Cancer Center in the Los Angeles area. Recently, he discussed the highly anticipated FLAURA2 trial during the World Conference on Lung Cancer in Singapore. In his words, “Hi, I’m Jack West. I’d like to talk about the FLAURA2 trial, which was among the most anticipated presentations at the just completed World Conference on Lung Cancer in Singapore.”

The FLAURA2 trial aimed to compare the efficacy of Osimertinib as a single agent versus Osimertinib combined with chemotherapy as a first-line treatment for patients with EGFR mutation-positive non-small cell lung cancer. The chemotherapy regimens included cisplatin or carboplatin with pemetrexed. A total of 557 patients were randomized in a 1-to-1 ratio between the single-agent and combination therapy groups.

Jack West noted, “What we saw was an improvement in progression-free survival, statistically significant and probably clinically …